Pregnancy Outcomes in HIV-Infected Women Receiving Long-Term Isoniazid Prophylaxis for Tuberculosis and Antiretroviral Therapy
Table 2
Association between adverse pregnancy outcomes and isoniazid and/or antiretroviral therapy during pregnancy in HIV-infected women, Isoniazid Preventive Therapy Trial, Botswana, 2005–2008 ().
Characteristic
Adverse outcome no. (%)
No adverse outcome no. (%)
uOR
95% CI
aOR
95% CI
Isoniazid exposure in pregnancy
Yes
32 (31.1)
71 (68.9)
0.6
0.3–1.1
0.6
0.3–1.1
No
40 (43.1)
53 (57.0)
1.0
1.0
Antiretroviral therapy regimen in pregnancy
Antiretroviral therapy (≥3 drugs from ≥2 classes)
34 (46.6)
39 (53.4)
2.0
1.1–3.5
1.8
0.9–3.6
Zidovudine or zidovudine/lamivudine only
38 (31.0)
85 (69.1)
1.0
1.0
Maternal CD4+ lymphocyte count nearest LNMP
<200 cells/mm3
13 (41.9)
18 (58.1)
1.3
0.6–2.8
1.0
0.4–2.5
≥200 cells/mm3
59 (35.8)
106 (64.2)
1.0
1.0
Maternal BMI near LNMP
Underweight <18.5
9 (52.9)
8 (47.1)
2.0
0.7–5.5
2.4
0.8–7.1
Not underweight ≥18.5
63 (35.8)
113 (64.2)
1.0
1.0
Maternal age (years)
—
—
1.1
1.0–1.1
1.1
1.0–1.2
BMI: body mass index; aOR: adjusted odds ratio (adjusted for all variables shown); CI: confidence interval; uOR: unadjusted odds ratio; LNMP: last normal menstrual period.
